Tomomi Oshima
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Tomomi Oshima has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Hideki Inoue
Department of Nephrology, Kumamoto University Graduate School of Medical Sciences, 1-1-1 Honjo, Chuo-ku, Kumamoto, Kumamoto 860-8556, Japan
3 shared publications- Hiroshi Nonoguchi
Division of Internal Medicine, Kitasato University Medical Center, 6-100 Arai, Kitamoto 364-8501, Saitama, Japan
3 shared publications - Katsumasa Kawahara
Department of Physiology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara 252-0374, Kanagawa, Japan
3 shared publications Kengo Yanagita
Department of Molecular Diagnostics, Kitasato University School of Allied Health Sciences, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa 252-0373, Japan
3 shared publications- Taiga Yamazaki
Division of Biomedical Research, Kitasato University Medical Center, 6-100 Arai, Kitamoto 364-8501, Saitama, Japan
3 shared publications - Takashi Fukuyama
Division of Biomedical Research, Kitasato University Medical Center, Kitamoto, Japan
3 shared publications
Latest Publications
- Open Access
- 6 July 2020
- Published by Springer Nature in Research Square
Differentiation of endogenous Erythropoietin and exogenous ESAs by Western blotting with deglycosylation
Doping tests for illegal use of erythropoiesis-stimulating agents (ESAs) have been developed. Here, we show a new Western blotting to distinguish endogenous erythropoietin (Epo, 35-38 kDa) and exogenous ESAs (epoetin alpha and beta; 38-42 kDa, darbepoetin alpha; 47-50 kDa, epoetin beta pegol; 93-110 kDa). In contrast, Liquid Chromatography/Mass Spectrometry analyzed all endogenous Epo and exogenous ESAs as delycosylated 22 kDa Epo, indicating that LC/MS analysis could not distinguish Epo and ESAs. We believe that our Western blotting is useful to protect against illegal use of ESAs.
- 6 July 2020
- Published by Springer Nature in Research Square
Open AccessDifferentiation of endogenous Erythropoietin and exogenous ESAs by Western blotting with deglycosylation
Doping tests for illegal use of erythropoiesis-stimulating agents (ESAs) have been developed. Here, we show a new Western blotting to distinguish endogenous erythropoietin (Epo, 35-38 kDa) and exogenous ESAs (epoetin alpha and beta; 38-42 kDa, darbepoetin alpha; 47-50 kDa, epoetin beta pegol; 93-110 kDa). In contrast, Liquid Chromatography/Mass Spectrometry analyzed all endogenous Epo and exogenous ESAs as delycosylated 22 kDa Epo, indicating that LC/MS analysis could not distinguish Epo and ESAs. We believe that our Western blotting is useful to protect against illegal use of ESAs.
- Open Access
- 26 June 2020
- Published by Wiley in Physiological Reports
- Vol. 8 (12) , e14485
Erythropoietin production by the kidney and the liver in response to severe hypoxia evaluated by Western blotting with deglycosylation
The glycosylated Epo production by the kidney in response to severe hypoxia increased by 10–20 times. Deglycosylated Epo production by the kidney showed 400‐fold increase by severe hypoxia.
- 26 June 2020
- Published by Wiley in Physiological Reports
- Vol. 8 (12) , e14485
Open AccessErythropoietin production by the kidney and the liver in response to severe hypoxia evaluated by Western blotting with deglycosylation
The glycosylated Epo production by the kidney in response to severe hypoxia increased by 10–20 times. Deglycosylated Epo production by the kidney showed 400‐fold increase by severe hypoxia.